PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Dabrafenib - Market size and forecast 2018-2023 Sorafenib - Market size and forecast 2018-2023 Vemurafenib - Market size and forecast 2018-2023 Encorafenib - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DRIVERS AND CHALLENGES Market drivers Market challenges PART 10: MARKET TRENDS PART 11: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 12: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Array BioPharma Inc. Bayer AG F. Hoffmann-La Roche Ltd. Novartis AG PART 13: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 14: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Product - Market share 2018-2023 (%) Exhibit 18: Comparison by product Exhibit 19: Dabrafenib - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Dabrafenib - Year-over-year growth 2019-2023 (%) Exhibit 21: Sorafenib - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Sales data of sorafenib Exhibit 23: Sorafenib - Year-over-year growth 2019-2023 (%) Exhibit 24: Vemurafenib - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Vemurafenib - Year-over-year growth 2019-2023 (%) Exhibit 26: Encorafenib - Market size and forecast 2018-2023 ($ millions) Exhibit 27: Encorafenib - Year-over-year growth 2019-2023 (%) Exhibit 28: Market opportunity by product Exhibit 29: Customer landscape Exhibit 30: Market share by geography 2018-2023 (%) Exhibit 31: Geographic comparison Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 33: North America - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in North America Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Europe - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Europe Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 39: Asia - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in Asia Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 42: ROW - Year-over-year growth 2019-2023 (%) Exhibit 43: Top 3 countries in ROW Exhibit 44: Key leading countries Exhibit 45: Market opportunity Exhibit 46: Patient assistance programs Exhibit 47: New cases of cancer in the US 2015 Exhibit 48: Alternative therapies based on BRAF kinase inhibitors for various oncology indications Exhibit 49: Side effects of BRAF kinase inhibitors Exhibit 50: Impact of drivers and challenges Exhibit 51: Approved drugs with respect to their cancer indications Exhibit 52: Expansion of research areas of BRAF kinase inhibitors Exhibit 53: Strategic alliances in global BRAF kinase inhibitors market Exhibit 54: Vendor landscape Exhibit 55: Landscape disruption Exhibit 56: Vendors covered Exhibit 57: Vendor classification Exhibit 58: Market positioning of vendors Exhibit 59: Array BioPharma Inc. - Vendor overview Exhibit 60: Array BioPharma Inc. - Business segments Exhibit 61: Array BioPharma Inc. - Organizational developments Exhibit 62: Array BioPharma Inc. - Geographic focus Exhibit 63: Array BioPharma Inc. - Key offerings Exhibit 64: Array BioPharma Inc. - Key customers Exhibit 65: Bayer AG - Vendor overview Exhibit 66: Bayer AG - Business segments Exhibit 67: Bayer AG - Organizational developments Exhibit 68: Bayer AG - Geographic focus Exhibit 69: Bayer AG - Segment focus Exhibit 70: Bayer AG - Key offerings Exhibit 71: Bayer AG - Key customers Exhibit 72: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 73: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 74: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 75: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 76: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 77: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 78: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 79: Novartis AG - Vendor overview Exhibit 80: Novartis AG - Business segments Exhibit 81: Novartis AG - Organizational developments Exhibit 82: Novartis AG - Geographic focus Exhibit 83: Novartis AG - Segment focus Exhibit 84: Novartis AG - Key offerings Exhibit 85: Novartis AG - Key customers Exhibit 86: Validation techniques employed for market sizing Exhibit 87: Definition of market positioning of vendors

BorgWarner Inc. Continental AG Eaton JTEKT Corp. Robert Bosch GmbH ZF Friedrichshafen AG